Xykaa LD Capsule is a combination analgesic and anti-inflammatory medication containing Diclofenac 25 mg and Paracetamol 325 mg per capsule. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Paracetamol (acetaminophen) provides analgesic and antipyretic effects primarily through central inhibition of prostaglandin synthesis. This synergistic combination enhances pain relief and reduces inflammation more effectively than either agent alone, making Xykaa LD Capsule suitable for managing mild to moderate pain associated with musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, dental pain, and postoperative pain. The recommended dosage should be strictly adhered to, as excessive intake may increase the risk of adverse effects such as gastrointestinal irritation, hepatotoxicity, and renal impairment. Caution is advised in patients with pre-existing liver or kidney dysfunction, peptic ulcer disease, or hypersensitivity to NSAIDs or paracetamol. Xykaa LD Capsule should be used under medical supervision, and patients are advised to report any signs of allergic reactions, gastrointestinal discomfort, or unusual symptoms promptly. This combination offers a balanced approach to pain management with both anti-inflammatory and analgesic benefits.